This expert consensus statement provides essential guidance for interventional cardiologists on the unique vascular toxicities, screening requirements, and cath lab management of cardio-oncology patients.
No takes yet. Share an insight, caveat, or question.
Supports heightened vigilance for vascular injury in cardio-oncology; leaves open optimal screening and intervention strategies pending prospective data.
Iliescu et al. (2016) studied this question. Cancer therapies significantly injure the vasculature, leading to increased need for invasive evaluation and management in the cardiac catheterization laboratory.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: